Browse the evidence

Extending nightly fasting duration is associated with improved glucoregulation (lower HbA1c) and longer sleep duration, which are proposed mechanisms for the reduced breast cancer recurrence risk.

A longer nightly fast helps your body regulate blood sugar better and may help you sleep longer. These improvements in metabolic health and sleep are likely why extending your fast might help prevent breast cancer from coming back.

Elevated levels of C18:0 sphingolipids (specifically ceramide) in skeletal muscle are associated with insulin resistance in humans, independent of body weight or obesity status.

If you are overweight or obese, your risk for insulin resistance is not determined by your weight alone. Some individuals with excess body fat maintain high insulin sensitivity, while others do not. This difference is linked to specific lipid levels (C18:0 sphingolipids) in your muscles. While you cannot easily measure this at home, the takeaway is that 'metabolically healthy obesity' exists, and metabolic health should be assessed independently of BMI.

Daily moderate alcohol consumption (25g ethanol) for 6 weeks improves insulin sensitivity and increases adiponectin levels in postmenopausal women.

For postmenopausal women who already drink moderately, continuing to consume about one standard drink (25g alcohol) daily with dinner may support insulin sensitivity and healthy adiponectin levels. This does not mean non-drinkers should start drinking, as the risks of alcohol outweigh these specific metabolic benefits for most people.

Chronic psychological or physical stress induces hypercortisolism, which promotes visceral adiposity and metabolic syndrome by inhibiting lipolysis and stimulating lipogenesis via glucocorticoid receptors.

If you carry weight around your midsection (visceral fat) and feel chronically stressed, your body may be biologically programmed to store fat there due to high cortisol levels. This is not just 'willpower'; cortisol directly blocks fat burning (lipolysis) and encourages fat storage (lipogenesis) in the abdomen. Addressing chronic stress through behavioral or physiological means is a critical component of managing visceral obesity and metabolic health, alongside diet and exercise.

Chronic stress and hypercortisolism inhibit the growth hormone (GH) axis and sex steroid production, which further promotes visceral fat accumulation and insulin resistance.

Long-term stress doesn't just raise cortisol; it also lowers your body's ability to burn fat by suppressing growth hormone and sex hormones like testosterone. This hormonal shift makes it harder to lose visceral fat and easier to gain it, creating a cycle that is difficult to break without addressing the underlying stress.

Targeted ablation of glucose-dependent insulinotropic polypeptide (GIP)-producing K cells in mice prevents high-fat diet-induced obesity and insulin resistance by reducing body weight, decreasing food intake, and increasing energy expenditure.

This preclinical study suggests that blocking the action of GIP-producing cells in the gut can protect against obesity and insulin resistance caused by a high-fat diet. The mechanism involves reduced food intake and increased energy expenditure. While this is not a human intervention, it highlights GIP as a potential therapeutic target for obesity.

Liver-derived extracellular vesicles (EVs) containing specific miRNAs (let-7e-5p, miR-210-3p, miR-31-5p) are secreted in response to lipid overload and directly target adipocytes to promote adipogenesis and lipogenesis, thereby remodeling adipose tissue.

This research highlights that liver health directly influences fat storage through biological signaling, not just caloric balance. While this doesn't provide a direct lifestyle fix, it suggests that improving liver metabolic health (e.g., reducing lipid overload) may naturally reduce the drive for adipose tissue expansion.

Geranylgeranyl diphosphate synthase (Ggpps) in the liver is required for the secretion of lipid-overload-responsive EVs; liver-specific deletion of Ggpps reduces adipose mass and improves glucose tolerance.

This identifies Ggpps as a key enzyme controlling liver-to-fat signaling. Future therapies might target Ggpps to modulate fat storage, but currently, maintaining liver health through diet is the primary way to manage this pathway.

Simulated night-shift work induces 24-hour rhythms in circulating metabolites (including amino acids and lipids) that are driven by externally imposed behavioral time cues (sleep/wake, feeding/fasting) rather than the central suprachiasmatic nuclei (SCN) circadian pacemaker.

If you work night shifts, your body's metabolic rhythms (how it processes fats and proteins) are likely shifting to match your sleep and eating schedule, not your internal biological clock. This misalignment is a key driver of metabolic risk. To mitigate this, consider aligning your eating windows strictly with your awake hours (time-restricted feeding) and maintaining consistent sleep schedules, as these behavioral cues strongly influence peripheral metabolism.

Intracellular regulation of thyroid hormone by deiodinases (D1, D2, D3) dictates tissue-specific metabolic outcomes, where local T3 activation promotes energy expenditure and lipid mobilization, while inactivation preserves energy stores.

Your body's metabolic rate isn't just determined by your thyroid gland's output, but by how your specific tissues process that hormone. Enzymes called deiodinases activate or deactivate thyroid hormone locally in organs like muscle and fat. This means two people with identical blood thyroid levels can have vastly different metabolic rates and fat storage tendencies depending on their tissue-specific enzyme activity.

Brown Adipose Tissue (BAT) activity and adaptive thermogenesis are critically dependent on local Type 2 Deiodinase (D2) activity converting T4 to T3, particularly in response to cold exposure.

Exposure to cold can activate Brown Adipose Tissue (BAT), which burns calories to generate heat. This process relies on local thyroid hormone activation by the enzyme D2. While this is a potent metabolic lever, its impact varies significantly between individuals based on the amount of active BAT they possess.

Type 3 Deiodinase (D3) inactivation of thyroid hormone is essential for pancreatic beta-cell maturation and insulin secretion; D3 deficiency leads to glucose intolerance and impaired insulin secretion.

Proper regulation of thyroid hormone inactivation (by D3) in the pancreas is crucial for normal insulin secretion. Disruption of this local balance can impair beta-cell function and contribute to glucose intolerance, independent of systemic thyroid status.

Morbidly obese women exhibit significantly lower striatal dopamine D2/3 receptor availability compared to non-obese controls, suggesting a hypodopaminergic state that may drive compulsive eating.

This research suggests that obesity in some individuals may be linked to a biological difference in brain reward systems (specifically lower dopamine receptors), which can make food feel less rewarding and drive compulsive eating. This is not a moral failing but a neurochemical factor. While this doesn't provide a direct 'fix,' it highlights why standard willpower-based approaches might fail for some and suggests that treatments addressing brain reward pathways could be beneficial.

Systemic nonselective beta-adrenergic stimulation via isoprenaline increases whole-body energy expenditure to levels comparable to cold exposure but does not activate brown adipose tissue (BAT) in humans.

Taking beta-agonists to boost metabolism via brown fat activation is likely ineffective in humans. While these drugs do increase calorie burning, they do so through other tissues (like skeletal muscle), not brown fat. Strategies relying on beta-agonists to target brown fat specifically are not supported by this evidence.

Normal human aging is characterized by a significant increase in mean daily serum cortisol levels and a decrease in DHEA, leading to an elevated cortisol-to-DHEA ratio that impairs stress recovery and accelerates neurodegeneration.

As you age, your body naturally produces more cortisol (stress hormone) and less DHEA (anti-aging hormone). This imbalance impairs your ability to recover from stress and increases the risk of cognitive decline, muscle loss, and metabolic issues. Managing stress and maintaining physical activity are critical to mitigating these hormonal shifts.

Chronic elevation of glucocorticoids (cortisol) in the elderly impairs the ability to recover from stressful stimuli and contributes to structural brain changes, including hippocampal atrophy and amygdala dysfunction.

Chronic stress leads to persistently high cortisol levels, which can shrink the hippocampus (memory) and overactivate the amygdala (fear/anxiety). This impairs your ability to bounce back from stressful events. Prioritizing stress management techniques is essential for preserving cognitive function and mental health as you age.

The age-related decline in DHEA and DHEAS, combined with stable or elevated cortisol, creates a high cortisol-to-DHEA ratio that contributes to immunosenescence, frailty, and increased mortality risk.

Your body's production of DHEA (an anti-aging hormone) drops significantly with age, while cortisol (stress hormone) often stays high. This imbalance weakens your immune system and contributes to frailty. Managing stress and maintaining physical activity are key to keeping this ratio in check.

Higher baseline plasma concentrations of perfluoroalkyl substances (PFASs), specifically PFOS and PFNA, are associated with greater weight regain during the 6-24 month period following a diet-induced weight loss, primarily in women.

If you are struggling to maintain weight loss, especially as a woman, be aware that environmental chemicals like PFAS (found in non-stick cookware, food packaging, and some water supplies) may blunt your metabolic recovery. This doesn't mean you should stop trying, but it highlights why standard diets might feel harder to maintain for some. Focus on building lean muscle mass to boost RMR, as this study suggests PFAS specifically blunts the natural increase in RMR that usually helps prevent weight regain.

Pregnancy complications such as gestational hypertension, preeclampsia, and intrauterine growth restriction (IUGR) increase the offspring's risk of adult hypertension, cardiovascular disease, and metabolic syndrome through epigenetic modifications and endothelial dysfunction.

If you were born prematurely or with low birth weight due to pregnancy complications, you may have a higher baseline risk for heart disease and diabetes. Regular monitoring of blood pressure and metabolic markers is advisable, even if you maintain a healthy lifestyle.

Low endogenous melatonin production (defined as urinary 6-SMT ≤8 μg/night) is NOT a useful predictor of response to melatonin therapy in insomnia patients.

You do not need to get your melatonin levels tested to decide if melatonin might help your sleep. The study shows that low melatonin levels do not predict whether you will respond to melatonin therapy. Instead, being over 65 is a better indicator of potential benefit.

SIRT1 regulates lipolysis in adipocytes by deacetylating and activating the transcription factor FoxO1, which directly stimulates the expression of the rate-limiting lipolytic enzyme ATGL.

This research explains the biological mechanism behind how caloric restriction and fasting might promote fat loss: by activating SIRT1, which then turns on the genes responsible for breaking down fat (ATGL). It suggests that lifestyle factors activating SIRT1 (like fasting) work by enhancing this specific genetic pathway rather than just through simple calorie counting.

A single administration of senolytic CAR T cells targeting uPAR eliminates senescent cells in aged mice, resulting in improved glucose tolerance, reduced fasting glucose, and enhanced exercise capacity.

This research suggests that targeting senescent cells via a single cellular therapy can reverse age-related metabolic decline and improve physical fitness in mice. While not yet available for human use, it highlights senolytics as a potential future intervention for longevity.

The scaffold protein βKlotho (KLB) is an absolute requirement for Fibroblast Growth Factor 21 (FGF21) to exert metabolic effects in vivo; without KLB, FGF21 cannot trigger signaling, alter gene expression, or improve metabolic health.

FGF21 is not a standalone fat-loss drug; it requires the presence of the protein Klotho Beta (KLB) to function. If KLB is absent or defective, FGF21 therapy will be ineffective. This highlights that metabolic treatments must target the entire receptor complex, not just the hormone itself.

Saturated fatty acids (SFAs) activate Toll-like receptor 4 (TLR4) in skeletal muscle and adipose tissue, triggering IKK and JNK kinases that phosphorylate IRS proteins on serine residues, thereby blocking insulin signaling and causing insulin resistance.

If you have insulin resistance or obesity, the type of fat you eat matters significantly. High intake of saturated fats (found in fatty meats, butter, cheese) can directly activate immune receptors in your muscle and fat cells, triggering inflammation that blocks insulin from working. Reducing saturated fat intake may help restore insulin sensitivity by lowering this specific inflammatory signaling.